Back to Search
Start Over
Radioimmunotherapy of glioblastoma multiforme - Current status and future prospects
- Source :
- Critical Reviews in Oncology/Hematology. 163:103395
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
-
Abstract
- Glioblastoma multiforme (GBM) or grade IV astrocytoma is the most diagnosed form of primary brain tumours in adults. Radioimmunotherapy (RIT), mostly in combination with conventional therapies, is presented in the current review as a therapeutic strategy of high potential in the management of GBM. A systematic literature search was performed following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) to identify clinical studies that employed a form of radioimmunotherapy using alpha- or beta-emitting radioisotopes. The available literature on RIT in GBM and high-grade gliomas is presented and discussed. The results suggest that this promising treatment approach merits further investigation in future clinical studies. Refereed/Peer-reviewed
- Subjects :
- Adult
0301 basic medicine
Oncology
medicine.medical_specialty
medicine.medical_treatment
alpha-emitting radioisotopes
glioblastoma multiforme
03 medical and health sciences
0302 clinical medicine
Internal medicine
beta-emitting radioisotopes
medicine
Humans
High potential
Therapeutic strategy
High-Grade Glioma
Radioisotopes
Brain Neoplasms
business.industry
glioblastoma
Astrocytoma
Glioma
Hematology
Radioimmunotherapy
medicine.disease
nervous system diseases
030104 developmental biology
Systematic review
030220 oncology & carcinogenesis
radioimmunotherapy
Glioblastoma
business
high-grade glioma
immunoconjugates
Systematic search
Subjects
Details
- ISSN :
- 10408428
- Volume :
- 163
- Database :
- OpenAIRE
- Journal :
- Critical Reviews in Oncology/Hematology
- Accession number :
- edsair.doi.dedup.....cdcd4f4dd2fbbcb7fb77953e0efaea8f
- Full Text :
- https://doi.org/10.1016/j.critrevonc.2021.103395